National Expenditure For False-Positive Mammograms And Breast Cancer Overdiagnoses Estimated At $4 Billion A Year
National Expenditure For False-Positive Mammograms And Breast Cancer Overdiagnoses Estimated At $4 Billion A Year
复制标题
DOI：
10.1377/hlthaff.2014.1087
复制
发表时间：
2015-04-01
期刊：
影响因子：
9.7
通讯作者：
Mandl, Kenneth D.
中科院分区：
文献类型：
--
作者：
Ong, Mei-Sing;Mandl, Kenneth D.
全民乳房X线摄影筛查与乳房X线摄影假阳性结果和乳腺癌过度诊断的大幅增加有关。但是，目前缺乏关于美国相关费用的数据。我们根据2011年至2013年702，154名女性的主要美国医疗保险计划的支出数据，介绍了40-59岁女性因假阳性乳房X光检查和乳腺癌过度诊断而产生的费用。在诊断后的12个月内，每次假阳性乳房X线检查、浸润性乳腺癌和导管原位癌的平均支出分别为852美元、51 837美元和12 369美元。这意味着国家每年的成本为40亿美元。与假阳性乳房X光检查和乳腺癌过度诊断相关的成本似乎比以前记录的要高得多。筛查有可能挽救生命。然而，在关于筛查合适人群的辩论中，必须考虑乳房X光检查假阳性结果和乳腺癌过度诊断的经济影响。
Populationwide mammography screening has been associated with a substantial rise in false-positive mammography findings and breast cancer overdiagnosis. However, there is a lack of current data on the associated costs in the United States. We present costs due to false-positive mammograms and breast cancer overdiagnoses among women ages 40-59, based on expenditure data from a major US health care insurance plan for 702,154 women in the years 2011-13. The average expenditures for each false-positive mammogram, invasive breast cancer, and ductal carcinoma in situ in the twelve months following diagnosis were $852, $51,837 and $12,369, respectively. This translates to a national cost of $4 billion each year. The costs associated with false-positive mammograms and breast cancer overdiagnoses appear to be much higher than previously documented. Screening has the potential to save lives. However, the economic impact of false-positive mammography results and breast cancer overdiagnoses must be considered in the debate about the appropriate populations for screening.